OB/GYN Clinical Alert
RSSArticles
-
What’s the Buzz about Measuring Ovarian Reserve?
Investigators have attempted to develop screening tests to measure the term “ovarian reserve.” It is important for clinicians to understand the usefulness and limitations of these screening tests and to be able to interpret the results for themselves and their patients.
-
Urinary and Bowel Symptoms in Women with Suspected Gynecological Malignancy
Pelvic floor disorders are common in women before surgery for suspected gynecological malignancy.
-
Early Menopause and CVD Risk: A Call for HRT?
A meta-analysis suggests that early menopause increases the risk of cardiovascular disease and all-cause mortality.
-
Treatment and Prevention of Preeclampsia
A recent study suggested that sildenafil could temporarily stabilize patients with preeclampsia, while improving blood flow to and from the placenta.
-
Can the Human Papillomavirus Vaccine Cure Cervical Dysplasia?
In this randomized, controlled trial, the HPV 16/18 vaccine did not hasten resolution of existing oncogenic HPV infections nor prevent persistent HPV 16/18 associated infection and cervical dysplasia recurrence after loop electrosurgical excisional procedure treatment.
-
Should Perimenopausal Women Consider Estrogen Therapy?
A population-based study found that premenopausal women with low ovarian reserve, as determined by low levels of anti-Müllerian hormone, have unfavorable cardiovascular disease profiles.
-
Smoking Cessation and Preterm Birth
A study using Ohio state birth data showed that women who stopped smoking by the end of the first trimester had the same rates of preterm birth as nonsmokers. Women who stopped in the second trimester had preterm birth rates similar to those who smoked all the way through pregnancy.
-
New Prescription Drug Labeling for Pregnant and Nursing Women
The FDA has updated the requirements for the pregnancy and lactation sections of drug labeling to allow pregnant women and their healthcare providers to be better informed about the risks and benefits of medications while pregnant or nursing. This article discusses the new Pregnancy and Lactation Labeling Rule that went into effect in June 2015 and is being phased in over the next three to five years.
-
PCOS and Hormonal Contraception: A Tale of Two Syndromes?
Emerging evidence supports that two metabolic phenotypes exist among women with PCOS. For metabolically healthy PCOS patients, managing menstrual symptoms, anovulation and androgen excess with COCs provides a simple and well-tolerated treatment regimen. In contrast, PCOS patients with metabolic syndrome are at high risk for type 2 diabetes, and COC use may contribute to hyperinsulinemia, adverse lipid changes, and endothelial changes associated with adverse cardiovascular risk. The use of a levonorgestrel intrauterine device combined with spironolactone (to manage hyperandrogenism) and metformin (to manage hyperinsulinism) may offer advantages to metabolically unhealthy PCOS patients.
-
Oligohydramnios: How to Best Diagnose It and What It Really Means
A multicenter randomized, clinical trial involving large numbers of patients has shown that using the maximal vertical pocket instead of the amniotic fluid index to detect oligohydramnios more than halves the amount of inductions for the diagnosis of oligohydramnios without affecting the overall outcome.